中国继续医学教育
中國繼續醫學教育
중국계속의학교육
CHINA CONTINUING MEDICAL EDUCATION
2015年
3期
232-232,233
,共2页
晚期肾癌%索拉非尼%高血压%临床疗效
晚期腎癌%索拉非尼%高血壓%臨床療效
만기신암%색랍비니%고혈압%림상료효
Advanced kidney cancer%Sorafenib%Hypertension%Clinical curative effect
目的:探讨晚期肾癌患者行索拉非尼治疗期间高血压发生率,进而总结降压治疗对索拉非尼疗效的预测关系。方法将我院接收的28例晚期肾癌患者作为研究对象,均给予其索拉非尼治疗,计算患者用药期间高血压发生率,总结其发生率与索拉非尼疗效之间的关系。结果本组28例患者经治疗后,治疗总有效率为82.1%,其中8例(占比为28.6%)见高血压,对患者行药物治疗与生活指导后,血压均稳定,未见索拉非尼停药或减量病例;高血压发生率与索拉非尼疗效关系比较并无显著差异(P<0.05)。结论晚期肾癌患者行索拉非尼治疗期间的高血压发生率较高,经治疗后血压均可控,且高血压发生率大小与索拉非尼疗效二者之间并无直接关系。
目的:探討晚期腎癌患者行索拉非尼治療期間高血壓髮生率,進而總結降壓治療對索拉非尼療效的預測關繫。方法將我院接收的28例晚期腎癌患者作為研究對象,均給予其索拉非尼治療,計算患者用藥期間高血壓髮生率,總結其髮生率與索拉非尼療效之間的關繫。結果本組28例患者經治療後,治療總有效率為82.1%,其中8例(佔比為28.6%)見高血壓,對患者行藥物治療與生活指導後,血壓均穩定,未見索拉非尼停藥或減量病例;高血壓髮生率與索拉非尼療效關繫比較併無顯著差異(P<0.05)。結論晚期腎癌患者行索拉非尼治療期間的高血壓髮生率較高,經治療後血壓均可控,且高血壓髮生率大小與索拉非尼療效二者之間併無直接關繫。
목적:탐토만기신암환자행색랍비니치료기간고혈압발생솔,진이총결강압치료대색랍비니료효적예측관계。방법장아원접수적28례만기신암환자작위연구대상,균급여기색랍비니치료,계산환자용약기간고혈압발생솔,총결기발생솔여색랍비니료효지간적관계。결과본조28례환자경치료후,치료총유효솔위82.1%,기중8례(점비위28.6%)견고혈압,대환자행약물치료여생활지도후,혈압균은정,미견색랍비니정약혹감량병례;고혈압발생솔여색랍비니료효관계비교병무현저차이(P<0.05)。결론만기신암환자행색랍비니치료기간적고혈압발생솔교고,경치료후혈압균가공,차고혈압발생솔대소여색랍비니료효이자지간병무직접관계。
ObjectiveTo study the hypertension incidence of patients with advanced kidney cancer accepted sorafenib treatment, and then summarize the curative effect of antihypertensive treatment on sorafenib predict relationship.Methods 28 cases of our hospital to receive advanced kidney cancer patients as the research object, have given the sorafenib treatment, patients during hypertension incidence, summarize the occurrence and the relationship between the sorafenib curative effect.Results 28 patients after treatment, the total effective rate was 82.1%, of which 8 cases (28.6%), high blood pressure, for patients after drug treatment and life guidance, blood pressure stable, did not see sorafenib withdrawal or decrement case. The incidence of hypertension compared with sorafenib curative effect relationship and there was no signiifcant difference (P<0.05).Conclusion Patients with advanced kidney cancer line sorafenib during treatment of a greater incidence of hypertension, blood pressure after treatment were controlled, and the incidence of hypertension size and sorafenib curative effect, there is no direct relationship between the two.